Thank you, Andrew, and good morning. IDEX delivered an exceptional third quarter driven by execution across all growth drivers, expansion of diagnostic utilization, growth in our global instrument and customer base, and continued delivery against our broad-based innovation pipeline. Our innovations work together as a solution across point of care, reference labs, and software to expand care and diagnostics utilization in the hands of our customers. IDEX diagnostics and software innovations are enabling more pets around the world to get the high quality care they deserve. This morning I'll focus my comments on three areas global commercial execution, diagnostics and software innovation delivery, and our acquisition of COVID. Our commercial execution was strong again this quarter, reflected in exceptional instrument placements, new customer acquisition, and volume driven growth ahead of sector averages. ? At the point of care, each instrument placement is a long term platform investment by the practice, and every menu addition grows the recurring value of that installed base. Our reference labs delivered another quarter of double digit growth, led by volume expansion, including strong pull through from Cancer DX. And in diagnostic imaging, we delivered a third consecutive quarter of more than 300 digital radiography placements driven by demand for the DR 50 plus. Customer retention in CAG diagnostics remains in the high 90s globally, reflecting the trust veterinarians place in IDEX and the durable value of our integrated solutions. We know from experience that diagnostics is a performance category. Practices that embrace our innovative platforms, point of care, reference labs, software and imaging see higher growth in both their diagnostics and overall practice revenue. Internationally, demand for IDEX innovations remains robust. The commercial expansions we announced on the Q2 call for France, Spain, South Korea, and Canada were all completed ahead of schedule. These investments follow our well proven playbook for accelerated sector development through smaller territories for increased customer proximity. When we work side by side with our customers to build our innovations into their everyday protocols, we see higher diagnostics adoption and utilization supporting practice growth. Turning to innovation, MVUDX momentum is strong, and we're well on track to exceed our placement goal of 5,500 for the year. Nearly half of our Q3 placements were international, showing that the value of this paradigm changing platform resonates with clinicians around the world. We added both nucleated red blood cells and eccentricytes to blood morphology in Q3. These updates push automatically to our global installed base of nearly 11,000 in viewDX instruments with no action required by the practice. ? At the start of the fourth quarter, we opened fine needle aspirate or FNA availability to all North American NVUDX customers, and every new North American placement now includes FNA. Every day, veterinarians face dogs with suspicious lumps and bumps and a pet parent worried about cancer. Today, only around 10% of these masses get assessed because of the cost and the complexity of glass slides and sending samples ? out. Early customers using FNA on InVUDX are evaluating twice as many masses. This is IDEX innovation, bending the cost curve to expand care access and care volume. We've also broadened what FNA can identify, adding lipomas and keratinized growth alongside mast cell tumor detection. A mast cell tumor can feel very similar to a lipoma, which is why examining the cells matters. With InVUDX, veterinarians can give owners answers and reassurance during the visit and focus on the masses that need attention. ? And if a mass needs further evaluation, a board certified IDEX pathologist review is one click away, which also brings more volume to our reference labs. For customers not currently using our lab, InVUDX placements also include onboarding to the IDEX reference lab for a seamless Experience. IDEX Cancer DX continues to be one of our most important innovations, filling a critical gap in care for early and specific cancer detection. Cancer is the top cause of mortality in dogs, with more than 25 million at-risk dogs globally. Tragically, cancer is often found too late to take action. Early detection expands treatment options and has the potential to extend a pet's life. ? In the third quarter, we delivered another milestone, adding canine mast cell tumor detection alongside canine lymphoma in North America, taking cancer DX from a test to a multi-cancer panel. Mast cell tumors are among the most common cancers in dogs and are frequently missed. We tune detection toward the more aggressive forms where early detection makes the greatest difference and a positive result is highly actionable. Mast cell tumor detection also connects directly to NVUDX. A positive result for mast cell tumor on cancer DX prompts a next step to examine any external masses for cancer using NVUDX FNA. This is the kind of connected solution IDEX can deliver across point of care and reference labs. As we shared at Investor Day, we're offering the expanded Cancer DX panel at the same affordable price as when we launched, as low as $15 in the U.S., when run with most blood work panels in the IDEX reference labs. Doctors and pet parents should never have to choose between early cancer screening and wellness blood work. These should be run together for at-risk dogs. Independent practices practices and corporate groups alike are welcoming our leadership stance on affordable screening. CancerDX runs on the same blood sample practices already send us for routine blood work, with no change to specimen requirements or workflow. We see strong evidence that our strategy to grow blood work utilization is working. 70% of Cancer DX runs are part of a broader blood work panel, and customers who adopt Cancer DX see higher higher routine testing volumes. ? By the end of the year, Cancer DX capabilities will expand further to include hemangiosarcoma detection, and we are planning for broad customer availability in North America beginning in the first quarter. Hemangiosarcomas grow silently inside an organ like the spleen, and are too often discovered only as an emergency when the mass ruptures and the dog can be lost within hours. This is a heartbreaking experience for owners and veterinarians alike. ? With homangiosarcoma, Cancer DX will address approximately 40% of all canine cancers. We believe this marks a tipping point for affordable cancer screening, inspiring broader wellness blood work. Earlier this month, we also advanced our technology for life platform strategy with the North American launch of Catalyst Pro-BMP, the first and only dual species quantitative cardiac test at the point of care. Heart disease affects approximately one in six cats and one in ten dogs, yet it remains underassessed in general practice, with only about 420 veterinary cardiologists in the U.S. for more than 23 million affected cats and dogs. Catalyst ProBMP supports screening, diagnosis, and monitoring across multiple clinical scenarios. It delivers quantitative results during the patient visit with laboratory level accuracy, so decisions can be made while the patient is still in the clinic, and results appear in VecConnect Plus with built-in interpretive guidance. Catalyst menu additions, such as SDMA inclusive clips, pancreatic lipase, cortisol, and now ProBMP, expand the value of our over 80,000 catalysts around the world.
Passages & reports (40) 16:20 Thank you, Andrew, and good morning. IDEX delivered an exceptional third quarter driven by… Report 16:39 pipeline. Our innovations work together as a solution across point of care, reference labs… Report 16:59 around the world to get the high quality care they deserve. This morning I'll focus my com… Report 17:19 this quarter, reflected in exceptional instrument placements, new customer acquisition, an… Report 17:29 At Report 17:29 the point of care, each instrument placement is a long term platform investment by the pra… Report 17:49 strong pull through from Cancer DX. And in diagnostic imaging, we delivered a third consec… Report 18:09 90s globally, reflecting the trust veterinarians place in IDEX and the durable value of ou… Report 18:29 labs, software and imaging see higher growth in both their diagnostics and overall practic… Report 18:49 Canada were all completed ahead of schedule. These investments follow our well proven play… Report 19:09 their everyday protocols, we see higher diagnostics adoption and utilization supporting pr… Report 19:28 placements were international, showing that the value of this paradigm changing platform r… Report 19:48 11,000 in viewDX instruments with no action required by the practice. Report 19:55 At Report 19:55 the start of the fourth quarter, we opened fine needle aspirate or FNA availability to all… Report 20:15 parent worried about cancer. Today, only around 10% of these masses get assessed because o… Report 20:27 out. Report 20:28 Early customers using FNA on InVUDX are evaluating twice as many masses. This is IDEX inno… Report 20:48 keratinized growth alongside mast cell tumor detection. A mast cell tumor can feel very si… Report 21:08 attention. Report 21:09 And Report 21:09 if a mass needs further evaluation, a board certified IDEX pathologist review is one click… Report 21:29 seamless Experience. IDEX Cancer DX continues to be one of our most important innovations,… Report 21:49 at-risk dogs globally. Tragically, cancer is often found too late to take action. Early de… Report 22:03 In Report 22:04 the third quarter, we delivered another milestone, adding canine mast cell tumor detection… Report 22:24 and are frequently missed. We tune detection toward the more aggressive forms where early … Report 22:43 cell tumor on cancer DX prompts a next step to examine any external masses for cancer usin… Report 23:03 offering the expanded Cancer DX panel at the same affordable price as when we launched, as… Report 23:23 and wellness blood work. These should be run together for at-risk dogs. Independent practi… Report 23:43 specimen requirements or workflow. We see strong evidence that our strategy to grow blood … Report 24:02 By Report 24:02 the end of the year, Cancer DX capabilities will expand further to include hemangiosarcoma… Report 24:22 often discovered only as an emergency when the mass ruptures and the dog can be lost withi… Report 24:36 With Report 24:36 homangiosarcoma, Cancer DX will address approximately 40% of all canine cancers. We believ… Report 24:56 also advanced our technology for life platform strategy with the North American launch of … Report 25:16 one in ten dogs, yet it remains underassessed in general practice, with only about 420 vet… Report 25:35 diagnosis, and monitoring across multiple clinical scenarios. It delivers quantitative res… Report 25:55 interpretive guidance. Catalyst menu additions, such as SDMA inclusive clips, pancreatic l… Report